Alfa Laval`s products are also used in power plants aboard shipsin the mechanical engineering industry in the mining industry and forwastewater treatment as

Alfa Laval`s products are also used in power plants, aboard ships,in the mechanical engineering industry, in the mining industry and forwastewater treatment, as well as for comfort climate and refrigerationapplications. Alfa Laval`s worldwide organization works closely with customers in nearly 100countries to help them stay ahead in the global arena. Alfa Laval is listed on the Nordic Exchange, Nordic Large Cap, and, in 2008,posted annual sales of about SEK 28 billion (approx 2.9 billion Euros) Thecompany has some 12 000 employees. Laval AB (publ) discloses the information provided herein pursuant to theSecurities Markets Act and/or the Financial Instruments Trading Act Theinformation was submitted for publication at 11:00 a.m on July 9, 2009. This information was brought to you by Cision http:// LavalPeter TorstenssonSenior Vice President, CommunicationsTel: + 46 46 36 72 31Mobile: +46 709 33 72 31orGabriella GrotteInvestor Relations ManagerTel: +46 46 36 74 82 Mobile: +46 709 78 74 82 Copyright Business Wire 2009. DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Israel Pharmaceuticals and Healthcare Report Q32009″ report to their offering. Pharmaceuticals and Healthcare Report provides industry professionals andstrategists, corporate analysts, pharmaceutical associations, governmentdepartments and regulatory bodies with independent forecasts and competitiveintelligence on Israel’s pharmaceutical and healthcare industry In BMI’s updated Business Environment Rankings (BER) for Q309, Israel continuedslipping down the table, now ranking seventh out of the 17 Middle East andAfrican (MEA) markets surveyed.

While the country scores strongly across thecountry structure and the country risk categories, a risky regulatoryenvironment, particularly in regard to intellectual provisions (IP) provisions,serves to limit Israel’s overall attractiveness for multinational drugmakers.Moreover, although Israel’s IP environment has been criticised for deterioratingin the past decade, the country seems to have no plans to improve the situation,which will continue to weigh down on Israel’s placement within BMI’s MEA matrix.In the meantime, Israel once again featured in the ‘Priority Watch List’ ofcountries with deficient IP regimes, which is produced as part of the 2009version of the Special 301 Submission by the Pharmaceutical Research andManufacturers of America (PhRMA). Key points of contention include the lack ofadequate patent and data exclusivity protection and regulatory approval delays.While the latter has been addressed to a degree, insufficient budgetary supportremains a major obstacle to establishing a better system for processingmarketing applications, which will continue to be biased against foreign madepatented drugs. In addition to the IP issues that stifle the development of the innovativepatented market segment, the economic situation (such as the forecast 1.8% GDPcontraction in 2009) and political environment will conspire to result in a slowgrowth of the Israeli pharmaceutical market over the next five years. From the2008 market value of ISL5.46bn (US$1.53bn) at retail prices, the market willgrow to just ILS5.98bn (US$1.57bn) in 2013, posting a compound annual growthrate (CAGR) of just 1.83% in local currency terms (and of just 0.62% in USdollar terms). Per capita spending on drugs will, however, stagnate at aroundUS$207 estimated in 2008, as cost-containment negates any volume increases.

Anincreasing reliance on imports of non-patented medicines will also subdue growthas the government seeks to cut healthcare costs. While prescription medicineswill continue to account for the majority of the market by value, economicrecovery will once again boost the uptake of OTCs, especially in the face of arestrictive pricing and reimbursement environment. In the meantime, Israeli healthcare coverage continues to be criticised byinternational bodies. In March 2009, the Physicians for Human Rights (PHR) groupcalled for amendments to the state policy prohibiting children who are notcurrently under permanent residential status access to healthcare. Despite thefact that Israeli legislation stipulates a basic healthcare package for foreignworkers, children continue to be excluded from the system due to inconsistentand unrealistic criteria that need to be met in order to qualify for the healthcoverage.